Senzar Asset Management Llc Position in Aerie Pharmaceuticals Inc (NASDAQ:AERI) Trimmed as Price Declined

May 17, 2018 - By Michele Cranor

Big Money Sentiment decreased to 1.2 in 2017 Q4. It has change of 0.53, from 2017Q3’s 1.73. The ratio worsened due to AERI positioning: 23 sold and 48 reduced. 21 funds acquired positions and 64 increased positions. Investors holded 34.42 million in 2017Q3 but now own 34.86 million shares or 1.29% more. Moreover, Jane Street Grp Ltd has 0% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Citigroup has invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Principal Financial Group Inc owns 15,406 shs for 0% of their capital. The Florida-based Harvey Capital Mgmt has invested 0.51% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Iguana Healthcare Management reported 3.31% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Moreover, Bancshares Of Nova Scotia has 0.01% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 22,200 shs. Aperio Grp Incorporated Lc reported 0% stake. 371,076 were reported by Alliancebernstein Lp. Kazazian Asset Mngmt Ltd Limited Liability Company, New York-based fund reported 12,466 shs. Tradewinds Cap Mngmt Ltd Liability Co has invested 0.01% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Tiaa Cref Inv Management Limited Liability Co accumulated 89,396 shs. 116,770 were accumulated by Dafna Cap Mngmt Ltd Com. Moreover, Sg Americas Secs Limited Liability Corporation has 0.01% invested in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) for 12,331 shs. United Advisers Limited Liability Com reported 0% stake. Ny State Common Retirement Fund reported 35,200 shs stake.

The stake In Aerie Pharmaceuticals Inc (NASDAQ:AERI) owned by Senzar Asset Management Llc was decreased. According to 2018Q1 SEC filling the decrease is 74.62%. The company’s stock declined 12.77% with the market as Senzar Asset Management Llc sold 207,732 shares. At the end of 2018Q1, the hedge fund held 70,668 shares of the health care company, priced at $3.83 million, down from 278,400 at the end of the previous reported quarter. $2.02 billion is Aerie Pharmaceuticals Inc’s market cap. AERI hit $51.2 during the last trading session after $0.8 change.Currently Aerie Pharmaceuticals, Inc. is uptrending after 16.25% change in last May 17, 2017. AERI has 224,990 shares volume. AERI outperformed by 4.70% the S&P500.

Senzar Asset Management Llc has risen its stake in and also increased its holding in by shares in the quarter, for a total of shares.

Senzar Asset Management Llc is a New York-based hedge fund with more than $442.00 million AUM in December, 2014. Taken from Senzar Asset Management latest Adv, the fund reported to have 7 full and part-time employees. Among which 4 performing investment advisory and research functions. The hedge fund had between 1-10 clients.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

In total 6 analysts cover Aerie Pharma (NASDAQ:AERI). “Buy” rating has 6, “Sell” are 0, while 0 are “Hold”. (NASDAQ:AERI) has 100% bullish analysts. 11 are the (NASDAQ:AERI)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. The stock rating was maintained by Canaccord Genuity with “Buy” on Wednesday, January 24. In Friday, February 16 report H.C. Wainwright reinitiated it with “Buy” rating and $78 target. On Tuesday, January 2 the stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) earned “Buy” rating by Stifel Nicolaus. In Monday, December 18 report Cantor Fitzgerald maintained the stock with “Buy” rating. On Thursday, March 29 the stock has “Buy” rating by Mizuho. In Wednesday, February 28 report Cantor Fitzgerald maintained it with “Buy” rating and $86.0 target. On Wednesday, May 9 the rating was maintained by Mizuho with “Buy”. On Tuesday, May 8 Cantor Fitzgerald maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating. Cantor Fitzgerald has “Buy” rating and $8600 target. On Thursday, March 1 the rating was maintained by H.C. Wainwright with “Buy”. On Wednesday, May 9 the firm has “Buy” rating given by H.C. Wainwright.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases.The firm is worth $2.02 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.Last it reported negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: